Combined chemotherapy and teratogenicity

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 73, Issue 9, 2005, Pages 634-637

  Paskulin, Giorgio Adriano ^a   Gazzola Zen, Paulo Ricardo ^a   De Camargo Pinto, Louise Lapagesse ^a   Rosa, Rafael ^a   Graziadio, Carla ^a  

^a UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

Author keywords

Birth defect; Chemotherapy; Malformation; Teratogenesis

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL;

ARTICLE; BIRTH DEFECT; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CASE REPORT; FACE MALFORMATION; HUMAN; MALE; MASTECTOMY; MICROCEPHALY; NAIL DYSPLASIA; NEWBORN; PREGNANCY; PRIORITY JOURNAL; SYNDACTYLY; TERATOGENICITY;

ABNORMALITIES, DRUG-INDUCED; ABNORMALITIES, MULTIPLE; ADULT; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DEVELOPMENTAL DISABILITIES; DOXORUBICIN; DRUG THERAPY, COMBINATION; FEMALE; FLUOROURACIL; HUMANS; MALE; MATERNAL-FETAL EXCHANGE; MICROCEPHALY; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; PREGNANCY TRIMESTER, THIRD; SYNDACTYLY; TERATOGENS;

EID: 26444609151     PISSN: 15420752     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdra.20180     Document Type: Article

References (12)

1. DiFronzo LA, O'Connell TX. 1996. Breast cancer in pregnancy and lactation. Surg Clin North Am 76:267-279.
2. Enns GM, Roeder E, Chan RT, et al. 1999. Apparent cyclophosphamide (Cytoxan) embryopathy: a distinct phenotype? Am J Med Genet 86:237-241.
3. Giannakopoulou C, Manoura A, Hatzidaki E, et al. 2000. Multimodal cancer chemotherapy during the first and second trimester of pregnancy: a case report. Eur J Obstet Gynecol Reprod Biol 91:95-97.
4. Greenberg LH, Tanaka KR. 1964. Congenital anomalies probably induced by cyclophosphamide. JAMA 188:423-426.
5. Kirshon B, Wasserstrum N, Willis R, et al. 1988. Teratogenic effects of first-trimester cyclophosphamide therapy. Obstet Gynecol 72:462-464.
6. Murray CL, Reichert JA, Anderson J, Twiggs LB. 1984. Multimodal cancer therapy for breast cancer in the first trimester of pregnancy. JAMA 252:2607-2608.
7. Mutchinick O, Aizpuru E, Grether P. 1992. The human teratogenic effect of cyclophosphamide. Aust Terat Abs 45:329,
8. cited by Enns GM, Roeder E, Chan RT, et al. 1999. Apparent cyclophosphamide (Cytoxan) embryopathy: a distinct phenotype? Am J Med Genet 86:237-241.
9. Paladini D, Vassallo M, D'Armiento MR, et al. 2004. Prenatal detection of multiple fetal anomalies following inadvertent exposure to cyclophosphamide in the first trimester of pregnancy. Birth Defects Res A Clin Mol Teratol 70:99-100.
10. Toledo TM, Harper RC, Moser RH. 1971. Fetal effects during cyclophosphamide and irradiation therapy. Ann Intern Med 74:87-91.
11. Vaux KK, Kahole NCO, Jones KL. 2003. Cyclophosphamide, methotrexate, and cytarabine embryopathy: is apoptosis the common pathway? Birth Defects Res A Clin Mol Teratol 67:403-408.
12. Zemlickis D, Lishner M, Erlich R, Koren G. 1993. Teratogenicity and carcinogenicity in a twin exposed in utero to cyclophosphamide. Teratog Carcinog Mutagen 13:139-143.